Aram Bidikian

Aram Bidikian is an academic researcher affiliated with the Department of Internal Medicine at Yale School of Medicine. His work focuses on hematologic malignancies, particularly acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). He investigates molecular mechanisms underlying these diseases, including the role of TP53 mutations, immune checkpoint modulation, and the impact of therapeutic agents like imetelstat and hypomethylating agents. Dr. Bidikian has contributed to clinical trials evaluating novel treatments and biomarkers for hematologic cancers.

Education

• Bachelor of Science (BS), American University of Beirut
• Doctor of Medicine (MD), American University of Beirut
• Research Fellowship in Internal Medicine, University of Texas MD Anderson Cancer Center

His research emphasizes translational approaches, integrating genomic data with clinical outcomes to improve patient care. Key areas include understanding treatment resistance mechanisms, optimizing hematopoietic cell transplant protocols, and identifying predictive biomarkers for therapy response. He collaborates on international consortia analyzing large clinical datasets to refine MDS/AML treatment strategies.

Recent studies highlight the immunosuppressive effects of somatic TP53 mutations in AML and the adverse impact of β-blockers on post-transplant hematopoietic recovery. His work bridges basic science and clinical practice, aiming to translate molecular insights into actionable therapies.